Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. Cassava Sciences, Inc. was incorporated in 1998 and is based in Austin, Texas.

• Download SqueezeTrigger (TM) Report
• Download FrictionFactor Report
• Download Daily Short Volume Report
• Download Real-Time Short Volume Tool
• Download Failures to Deliver

• [07/08/2025 07:18 PDT] SAVA Expected to Trade Up After Bullish Patterns Develop
• [07/07/2025 09:45 PDT] SAVA Expected to Trade Up After Bullish Patterns Develop
• [05/21/2025 07:28 PDT] SAVA Expected to Trade Down After Bearish Patterns Develop